首页> 外文期刊>Fish & Shellfish Immunology >Development and efficacy of feed-based recombinant vaccine encoding the cell wall surface anchor family protein of Streptococcus agalactiae against streptococcosis in Oreochromis sp.
【24h】

Development and efficacy of feed-based recombinant vaccine encoding the cell wall surface anchor family protein of Streptococcus agalactiae against streptococcosis in Oreochromis sp.

机译:基于饲料的重组疫苗的开发和功效,该疫苗编码无乳链球菌的细胞壁表面锚定家族蛋白,可抵抗Oreochromis sp。中的链球菌病。

获取原文
获取原文并翻译 | 示例
           

摘要

This study was carried out to determine the antibody responses and protective capacity of an inactivated recombinant vaccine expressing the cell wall surface anchor family protein of Streptococcus agalactiae following oral vaccination against streptococcosis in tilapia. Tilapia were vaccinated orally with 106 CFU/mL of the recombinant vaccine incorporated in feed (feed-based recombinant vaccine) (vaccinated group or Group 1), 106 CFU/mL of pET-32 Ek/LIC vector without cell wall surface anchor family protein (control group or Group 2), 106 CFU/mL of formalin-killed cells of S. agalactiae vaccine incorporated in feed was also prepared (feed-based vaccine) (vaccinated group or Group 3), and unvaccinated control group or Group 4 (fed with commercial pellets). During the course of study, serum, mucus and gut lavage fluid were collected to evaluate the antibody levels via enzyme-linked immunosorbent assay (ELISA). The results showed that tilapia immunized with the feed-based recombinant vaccine developed a strong and significantly (P<0.05) higher IgM antibody response in serum, mucus and gut lavage fluid samples compared to groups 2, 3 and 4. Following heat intervenes and intraperitoneal challenge, the rate of survivors (RPS) was 70% for the vaccinated group, and 0% for the rest of the groups. Therefore, the study revealed that the feed-based recombinant vaccine significantly provides high protection against high dose challenge in heat stress environment and enhances the production of the mucosal and humoral immunity.
机译:进行这项研究以确定口服预防罗非鱼链球菌病接种后表达无乳链球菌细胞壁表面锚定家族蛋白的灭活重组疫苗的抗体反应和保护能力。罗非鱼经10 6 CFU / mL掺入饲料的重组疫苗(基于饲料的重组疫苗)(接种组或第1组),10 6 CFU /饲料中掺入无细胞壁表面锚定家族蛋白的pET-32 Ek / LIC载体(对照组或第2组),10 6 CFU / mL福尔马林杀死的无乳链球菌疫苗细胞,还准备了(基于饲料的疫苗)(接种疫苗的组或第3组)和未接种疫苗的对照组或第4组(用商业颗粒饲料喂养)。在研究过程中,通过酶联免疫吸附测定(ELISA)收集血清,粘液和灌肠液以评估抗体水平。结果显示,与第2、3和4组相比,以饲料为基础的重组疫苗免疫的罗非鱼在血清,黏液和灌肠液中的IgM抗体反应强度更高(P <0.05),且显着更高(P <0.05)。挑战中,接种组的存活率(RPS)为70%,其余组为0%。因此,该研究表明,以饲料为基础的重组疫苗在热应激环境中显着提供了针对高剂量挑战的高度保护作用,并增强了粘膜和体液免疫的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号